Treatment protocols for chronic myelogenous leukemia (CML) are provided below for chronic phase, accelerated phase, and blast phase. General treatment recommendations for chronic myelogenous leukemia Tyrosine kinase inhibitors (TKIs) are the drugs of choice for initial therapy of CML. [1] Imatinib was...
The goals of treatment of chronic myelogenous leukemia (CML) are threefold and have changed markedly since the advent of tyrosine kinase inhibitor (TKI) therapy. They are as follows: Hematologic remission (normal complete blood cell count [CBC] and physical examination (ie, no organomegaly) Cytoge...
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single- institution historical experience. Blood. 2012; 119(9):1981-1987.Kantarjian H, O'Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy...
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia—what to look for when treatment-free remission is not an option. Blood Rev. 2022;56: 100968. Article CAS PubMed Google Scholar Kantarjian HM, et al. A review of the therapeutic role of bosutinib in chronic...
While in T cell acute lymphoblastic leukemia, treatment modifies cellular metabolism from glutaminolysis to glycolysis to evade drug-induced cellular stress. One glycolytic enzyme important in cancer is pyruvate kinase M2 (PKM2) that provides a survival advantage to diseased cells and plays a role in...
To determine in real-life conditions the safety of treatment with rituximab (RTX) in patients with rheumatoid arthritis (RA) regarding malignancies. Analys... S Slimani,C Lukas,B Combe,... - 《Joint Bone Spine Revue Du Rhumatisme》 被引量: 39发表: 2011年 Conditional survival in pediatric ...
Figure. Survival of BC patients after treatment with imatinib; data of the German CML Study IV Disclosures: German CML Study Group: Deutsche Krebshilfe: Research Funding; Novartis: Research Funding; German CompetenceNet : Research Funding; European LeukemiaNet: Research Funding; Roche: Research Fundin...
Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002; 100: 1014–1018. 94 Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D et al. High-...
The progression rate was significantly lower in patients treated with IM than in those treated without IM (0 vs. 28.6%, p=0.006). In summary, the survival outcomes of pediatric patients with CML were dramatically improved by treatment with IM compared to HSCT. 展开 ...
We’ve learned that the rates of progression are lower with nilotinib than imatinib, especially again in the first year. We’ve learned that there’s no statistically significant difference in survival, but if you look at CML-related deaths, there was clearly a decrease in the number of CML...